Electromed, Inc. filings document formal disclosures for a Minnesota operating company focused on airway clearance technologies. Recent Form 8-K reports furnish quarterly financial results, Regulation FD investor presentations, share repurchase authorization disclosures, and material financing information tied to a senior secured revolving credit facility.
The company's proxy and shareholder-vote filings cover director elections, auditor ratification, advisory executive compensation votes, board and governance matters, and equity-compensation disclosures. These records also describe capital-allocation actions, debt covenants, financial condition updates, and exhibit materials associated with press releases, credit agreements, and investor presentations.
Electromed, Inc. (ELMD) reported higher revenue and earnings for the three months ended September 30, 2026. Net revenues were $18.682 million, up 10.6% from $16.887 million; homecare revenue was $17.506 million, up 17.6%. Operating income was $3.489 million, up 30.7%, and net income was $2.761 million, up 29.3%, versus $2.136 million. Diluted earnings per share were $0.32, compared with $0.25.
Operating cash flow was $373,000 versus $169,000; cash and cash equivalents were $15.875 million at September 30, 2026, compared with $20.450 million at June 30, 2026. Financing activities used $4.746 million, including $4.328 million for share repurchases. During the quarter, 157,341 shares were purchased under the repurchase authorization; approximately $1.755 million remained under its $10.0 million limit.
The company reported approximately $44.933 million in working capital and said it expects working capital and available credit to provide sufficient liquidity for anticipated needs over the next 12 months. Its $10.0 million revolving credit facility had no principal outstanding as of September 30, 2026, and matures December 16, 2026, if not renewed or replaced.
Electromed, Inc. reported first-quarter fiscal 2027 net revenue of $18.7 million for the three months ended September 30, 2026, up 10.6% from $16.9 million a year earlier. Direct homecare revenue rose 17.6% to $17.5 million, primarily due to more sales representatives and higher productivity. The company averaged 63 homecare field sales representatives; annualized homecare revenue per weighted average direct sales representative was $1,109,000, within its $1,050,000 to $1,150,000 target for the year.
Gross profit was $14.9 million, or 80.0% of revenue, versus $13.2 million and 78.1%. Operating income increased 30.7% to $3.5 million; net income rose 29.3% to $2.8 million, and diluted earnings per share were $0.32 versus $0.25. SG&A expenses rose 8.6% to $11.2 million, primarily reflecting higher salaries, incentive compensation, travel and meals tied to headcount, and higher overall compensation costs.
Operating cash flow was $373,000, compared with $169,000. As of September 30, 2026, Electromed had $15.9 million in cash and no debt. Cash decreased $4.6 million during the quarter, primarily due to $4.3 million of common-stock repurchases; shareholders’ equity was $52.5 million.
Electromed, Inc. asks shareholders to vote at its virtual annual meeting on November 13, 2026, on four matters: electing seven director nominees and setting the Board at seven, ratifying RSM US LLP for fiscal 2027, advisory approval of executive compensation, and approval of the Employee Stock Purchase Plan. The Board recommends voting FOR each proposal.
The Board approved the proposed ESPP on August 21, 2026, subject to shareholder approval; it would become effective upon approval within 12 months. The plan would reserve 750,000 shares, approximately 9% of the 8,287,085 shares outstanding on September 16, 2026. Its purchase price would be the lesser of 85% of fair market value on the first or last trading day of a purchase period. James L. Cunniff, President and Chief Executive Officer, plans to retire from all company positions on or about April 2, 2027, and the Board is conducting a search for his successor. Fiscal 2026 net income was $11.301 million, compared with $7.537 million in fiscal 2025.
Electromed, Inc. (ELMD) reported that its Chief Financial Officer, Bradley M. Nagel, received equity awards on September 1, 2026. He was granted 9,600 stock options with an exercise price of $27.10 per share, scheduled to vest in three substantially equal annual installments on September 1, 2027, September 1, 2028, and September 4, 2029. He also received 4,900 shares of restricted stock, which are scheduled to vest on the same three dates. In connection with the vesting of previously awarded restricted stock, 1,102 shares were forfeited at $27.10 per share to satisfy tax withholding obligations. No Rule 10b5-1 trading plan is reported for these transactions.
Electromed, Inc. (ELMD) reported that CEO and President James L. Cunniff had 2,671 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations related to the vesting of previously awarded restricted stock. After this tax-withholding disposition, he directly holds 145,080 shares of Electromed common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Electromed, Inc. (ELMD) reported record results for the fourth quarter and fiscal year ended June 30, 2026, and announced a planned CEO transition. Fiscal 2026 net revenues increased 15.3% to $73.8 million, led by direct homecare revenue up 16.3% to $66.6 million. Gross profit rose to $57.9 million with a gross margin of 78.5%. Operating income grew to $13.9 million, or 18.8% of net revenues, compared to 15.1% in fiscal 2025. Net income was $11.3 million, or $1.30 per diluted share, up from $7.5 million or $0.85.
For Q4 2026, net revenues increased 11.6% to $19.4 million, with net income of $3.4 million and diluted EPS of $0.39. The company highlighted its 15th consecutive quarter of year-over-year revenue and profit growth and homecare revenue per sales representative of $1,145,000, above its $1,000,000–$1,100,000 target range. As of June 30, 2026, Electromed had $20.5 million in cash, no debt, working capital of $45.1 million, and shareholders’ equity of $54.0 million.
Electromed also disclosed that President and CEO Jim Cunniff notified the company of his intention to retire on or about April 2, 2027, and is expected to resign from the Board at that time. The Board has engaged an executive search firm and begun a comprehensive search for the next CEO.
Electromed, Inc. (ELMD) develops and sells the SmartVest high frequency chest wall oscillation systems for airway clearance, primarily to U.S. homecare patients with bronchiectasis, COPD overlap, cystic fibrosis and neuromuscular conditions, using a direct-to-patient and provider model that captures both manufacturer and distributor margins.
For the year ended June 30, 2026, net revenues were $73.8 million, up 15.3% from 2025, led by 16.3% homecare growth. Gross profit was $57.9 million with a 78.5% gross margin. Operating income rose to $13.9 million, and net income increased 49.9% to $11.3 million, or $1.30 diluted EPS. R&D spending was $1.3 million, focused on product enhancements and clinical evidence.
Electromed ended 2026 with $20.5 million in cash, no borrowings on a $10 million revolving credit facility, and total shareholders’ equity of $54.0 million. The company repurchased 151,911 shares in fiscal 2026 and estimates HFCWO penetration of roughly 16% among about one million diagnosed U.S. bronchiectasis patients, highlighting a large underpenetrated market, while remaining heavily dependent on Medicare, Medicaid and private payer reimbursement.
Electromed, Inc. Chief Financial Officer Bradley M. Nagel reported a small share disposition related to taxes, not an open-market trade. On the reported date, 674 shares of common stock were forfeited at $42.30 per share to cover tax withholding when previously awarded restricted stock vested. After this tax-withholding event, Nagel directly held 18,964 shares of Electromed common stock, indicating the transaction was routine and left his overall ownership largely unchanged.
Electromed, Inc. CEO and President James L. Cunniff reported a combination of stock sales and an option exercise involving the company’s common stock. On June 8, 2026, he sold a total of 9,700 shares in three open-market transactions at weighted average prices of $37.7729, $36.7975, and $36.2490 per share. The same day, he exercised employee stock options to acquire 9,700 shares at an exercise price of $17.25 per share. Following these transactions, he directly holds 147,751 shares of Electromed common stock.